<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-24T10:28:53Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/346494" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/346494</identifier><datestamp>2023-12-22T13:03:51Z</datestamp><setSpec>com_1810_721</setSpec><setSpec>com_1810_256064</setSpec><setSpec>col_1810_218856</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>Protein and Peptide Solubility - In Silico and In Vitro Approaches</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">10.17863/CAM.93911</dc:identifier>
   <dc:creator>Oeller, Marc</dc:creator>
   <uketdterms:authoridentifier xsi:type="uketdterms:ORCID">0000000305975950</uketdterms:authoridentifier>
   <uketdterms:advisor>Vendruscolo, Michele</uketdterms:advisor>
   <dcterms:abstract>Solubility is a crucial property to optimise in the development of peptides and proteins
as therapeutic compounds. Biologics, which are drugs based on biological
compounds such as proteins, inherently possess many beneficial properties such as
low toxicity and high specificity. Often, however, they exhibit only limited solubility,
which makes them unsuitable to be developed into drugs. Screening out molecules
of insufficient solubility is a standard step used in drug development. Usually, this
step is done in vitro, at a late stage in the process as it is expensive. In silico methods,
at least in principle, offer the advantage of reducing the cost of this screening, while
simultaneously eliminating unsuitable candidates much earlier in the process. One
such method is CamSol [1], a sequence-based solubility predictor developed in the
Centre for Misfolding Diseases, to assess and improve the solubility of proteins.
The goal of this PhD was to develop a new method, built upon the foundations of
CamSol, that predicts the solubility of proteins and peptides containing non-natural
amino acids and to incorporate the effects of formulation pH. A particularly exciting
aspect of this project concerning the translation into industrial applications, is that it
was carried out in collaboration with AstraZeneca.
The effects of pH on the solubility of proteins are well understood at least in outline,
but there are no sequence-based methods that can reliably predict the solubility of
biologics at varying pH values. Similarly, no prediction method is currently capable
of assessing the effects of non-natural amino acids on the solubility of proteins. On
the experimental side, a high-throughput, low material requirement in vitro method
was developed to measure the solubility of proteins and peptides to verify the predictions.
Our results show that the correlation between the predicted and measured
solubilities is high, confirming that these new capabilities of CamSol are valid tools
that can be employed to facilitate drug development.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2022-08-26</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>Doctor of Philosophy (PhD)</uketdterms:qualificationname>
   <dc:language>eng</dc:language>
   <uketdterms:sponsor>The project was funded by AstraZeneca</uketdterms:sponsor>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/346494</dcterms:isReferencedBy>
   <dc:identifier xsi:type="dcterms:URI">https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/9622080a-7fbf-44e0-be9a-2343168c839c/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">181bcd4c4366b63690955998c6126fb4</uketdterms:checksum>
   <dc:rights>https://www.rioxx.net/licenses/all-rights-reserved/</dc:rights>
   <dc:subject>Protein Solubility</dc:subject>
   <dc:subject>Peptide Solubility</dc:subject>
   <dc:subject>Solubility Prediction</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>